Related references
Note: Only part of the references are listed.The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment
Mohammad Farhad et al.
ONCOIMMUNOLOGY (2018)
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
Xinqi Wu et al.
ONCOIMMUNOLOGY (2018)
The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
Cristina Vajaitu et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Predictors of responses to immune checkpoint blockade in advanced melanoma
N. Jacquelot et al.
NATURE COMMUNICATIONS (2017)
Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis
Jie-Hui Zhong et al.
ONCOTARGET (2017)
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
Sacha Gnjatic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M. Hopkins et al.
BRITISH JOURNAL OF CANCER (2017)
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab
Jon Bjoern et al.
ONCOIMMUNOLOGY (2016)
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al.
CLINICAL CANCER RESEARCH (2016)
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016
Claus Garbe et al.
EUROPEAN JOURNAL OF CANCER (2016)
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
Leila Khoja et al.
CANCER MEDICINE (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
Christoffer Gebhardt et al.
CLINICAL CANCER RESEARCH (2015)
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prognostic relevance of LGALS3BP in human colorectal carcinoma
Enza Piccolo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MicroRNA biogenesis pathways in cancer
Shuibin Lin et al.
NATURE REVIEWS CANCER (2015)
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
C. Lebbe et al.
ANNALS OF ONCOLOGY (2014)
Serum endostatin levels are elevated in colorectal cancer and correlate with invasion and systemic inflammatory markers
T. Kantola et al.
BRITISH JOURNAL OF CANCER (2014)
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
Ester Simeone et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
J. Delyon et al.
ANNALS OF ONCOLOGY (2013)
Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer
Tibor Szarvas et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Function but not phenotype of melanoma peptide-specific CD8+ T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)
Carsten Schaefer et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Role of systemic inflammatory response in predicting survival in patients with primary operable cancer
Campbell S. D. Roxburgh et al.
FUTURE ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Expression of b-FGF and endostatin and their clinical significance in human osteosarcoma
Chao-jian Xu et al.
Orthopaedic Surgery (2010)
Tumor stroma derived biomarkers in cancer
Malin Sund et al.
CANCER AND METASTASIS REVIEWS (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Expression pattern and circulating levels of endostatin in patients with pancreas cancer
Daniel Ohlund et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Tumour-released exosomes and their implications in cancer immunity
M. Iero et al.
CELL DEATH AND DIFFERENTIATION (2008)
Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?
Sandra R. Reynolds et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma
IJ Vergilis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Endostatin's antiangiogenic signaling network
A Abdollahi et al.
MOLECULAR CELL (2004)
Are 90K/MAC-2BP serum levels correlated with poor prognosis in HCC patients? Preliminary results
PA Iacovazzi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2003)
The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells
A Hajitou et al.
FASEB JOURNAL (2002)
Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1
YM Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions
AM Cesinaro et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2002)
Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival
L Strizzi et al.
JOURNAL OF PATHOLOGY (2002)
90K (Mac-2 BP) and galectins in tumor progression and metastasis
A Grassadonia et al.
GLYCOCONJUGATE JOURNAL (2002)
Generation and degradation of human endostatin proteins by various proteinases
M Ferreras et al.
FEBS LETTERS (2000)
The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing
AC Berger et al.
JOURNAL OF SURGICAL RESEARCH (2000)
Share Paper
